Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 6, 2012, Pages 557-564

  Pires, L A ^a   Hegg, R ^a   Freitas, F R ^a   Tavares, E R ^a   Almeida, C P ^a   Baracat, E C ^a   Maranhao R C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast cancer; Chemotherapy; Drug delivery; LDL receptor; Lipoproteins; Lrp 1 receptor; Nanoemulsion

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; BREAST BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE LUNG CARCINOMA; MALE; MASTECTOMY; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 84862010993     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500068     Document Type: Article

References (36)

1. Goldstein JL, Anderson RG, Brown MS. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 1979; 279: 679-685.
2. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelog-enous leukemia cells. Blood 1978; 52: 1099-1114.
3. Gal D, MacDonald PC, Porter JC, Simpson ER. Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism. Int J Cancer 1981; 28: 315-319.
4. Vitols S, Peterson C, Larsson O, Holm P, Aberg B. Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo. Cancer Res 1992; 52: 6244-6247.
5. Rudling MJ, Stahle L, Peterson CO, Skoog L. Content of low density lipoprotein receptors in breast cancer tissue related to survival of patients. Br Med J 1986; 292: 580-582.
6. Rudling MJ, Collins VP, Peterson CO. Delivery of aclacino-mycin A to human glioma cells in vitro by the low-density lipoprotein pathway. Cancer Res 1983; 43: 4600-4605.
7. Lundberg B. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res 1987; 47: 4105-4108.
8. Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids 1993; 28: 691-696.
9. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M. Increased expression of low density lipopro-tein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res 1997; 57: 2799-2805.
10. Strickland DK, Kounnas MZ, Argraves WS. LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J 1995; 9: 890-898.
11. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108: 779-784.
12. Brown MS, Herz J, Kowal RC, Goldstein JL. The low-density lipoprotein receptor-related protein: double agent or decoy? Curr Opin Lipid 1991; 2: 65-72.
13. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A 1989; 86: 5810-5814.
14. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992; 269: 375-382.
15. Henriksson P, Eriksson M, Ericsson S, Rudling M, Stege R, Berglund L, et al. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 1989; 2: 1178-1180.
16. Graziani SR, Igreja FA, Hegg R, Meneghetti C, Brandizzi LI, Barboza R, et al. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol Oncol 2002; 85: 493-497.
17. Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol 2009; 63: 281-287.
18. Mendes S, Graziani SR, Vitorio TS, Padoveze AF, Hegg R, Bydlowski SP, et al. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy. Gynecol Oncol 2009; 112: 400-404.
19. Teixeira LC, Pinotti JA. Câncer da mama: Quimioterapia. In: Halbe HW (Editor), Tratado de Ginecologia. Vol. 3. São Paulo: Editora Roca; 2000. p 2019-2022.
20. Iwanik MJ, Shaw KV, Ledwith BJ, Yanovich S, Shaw JM. Preparation and interaction of a low-density lipoprotein:daunomycin complex with P388 leukemic cells. Cancer Res 1984; 44: 1206-1215.
21. Masquelier M, Vitols S, Peterson C. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res 1986; 46: 3842-3847.
22. Maranhão RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, et al. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol 2002; 49: 487-498.
23. Maranhão RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM, Coelho IJ, et al. Plasma kinetics and biodistri-bution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 1994; 54: 4660-4666.
24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
25. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. New York: Springer-Verlag; 2010.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
27. Ades A, Carvalho JP, Graziani SR, Amancio RF, Souen JS, Pinotti JA, et al. Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. Gynecol Oncol 2001; 82: 84-87.
28. Azevedo CH, Carvalho JP, Valduga CJ, Maranhão RC. Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. Gynecol Oncol 2005; 97: 178-182.
29. De Vries TJ, Verheijen JH, de Bart AC, Weidle UH, Ruiter DJ, van Muijen GN. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. Cancer Res 1996; 56: 1432-1439.
30. Pinheiro KV, Hungria VT, Ficker ES, Valduga CJ, Mesquita CH, Maranhão RC. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother Pharmacol 2006; 57: 624-630.
31. Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Ma-ranhão RC. Pharmacokinetics and tumor uptake of a de-rivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother Pharmacol 2007; 59: 105-111.
32. Teixeira RS, Valduga CJ, Benvenutti LA, Schreier S, Ma-ranhão RC. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J Pharm Pharmacol 2008; 60: 1287-1295.
33. Lo Prete AC, Maria DA, Rodrigues DG, Valduga CJ, Ibanez OC, Maranhão RC. Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nano-emulsion. J Pharm Pharmacol 2006; 58: 801-808.
34. Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibanez OC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol 2005; 55: 565-576.
35. Teixeira RS, Curi R, Maranhão RC. Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE). J Pharm Pharmacol 2004; 56: 909-914.
36. Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski S P, Chi-attone CS, Maranhão RC. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 2004; 53: 51-60.